0
What is the maximum plasma level of tamoxifen that can be achieved in breast cancer patients?
- 1 people answered
0 Vote
1 Contributor
1356 Views 
0 Saved
0 Vote 1 Contributor1356 Views 0 SavedYou might also be interested in
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epitheli....
Surgery is only the first step towards fuller and more beautiful breasts. Following your breast enhancement surgery, the recovery period is a crucial time during which your body heals and your new breast implants settle into their proper position and shape. Following Breast Implant surgery you ca....
One can start driving after 6 weeks post-surgery to be on the safer side. If other additional treatments are going on, it is best to ask your doctor for such instructions.
Mithun Kumar
Tamoxifen is a highly effective endocrine treatment for breast cancer in the adjuvant and metastatic settings. Data from several large randomized clinical trials indicate that tamoxifen is also valuable in the prevention of breast cancer in women at high risk for the disease. However, not all women benefit from tamoxifen, and the side effect profiles vary considerably from patient to patient.
Tamoxifen treatment promotes significant changes both in the plasma concentration of an important marker associated with an increased risk of Cardio Vascular Disease (CVD) and in functional parameters of cardiac performance in women with breast cancer who have previously undergone chemotherapy. Previous studies had also confirmed the cardiotoxic effects of chemotherapy.
Chronic use of tamoxifen significantly reduces the plasma concentrations of CVD biomarkers (CRP, Apo B, and the Apo-B/Apo-A ratio) in women with breast cancer who underwent chemotherapy. Several study suggests the need for a careful cardiovascular evaluation and the medical monitoring of women with breast cancer to reduce the morbidity and mortality associated with cancer treatment complications.